Attralus, Inc.
Therapeutics targeting amyloid removal for amyloidosis patients
- Sector
- Biotech
- Headquarters
- Burlingame, CA
- Founded
- 2019
- Latest Form D
- $56M, Feb 2024
- Total capital
- $173M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $173M
- 3 Form D · last Feb 2024
- 33 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 11 pending · first 2024
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$56M
- Private capital raisedForm D · SEC · 2nd filing$117M
- Private capital raisedForm D · SEC · 1st filing$175K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Jonathan WallResearcherExecutive OfficerLinked by 1 patent
- Alex DennerDirectorNamed in SEC Form D filings
- Benson FongExecutive OfficerNamed in SEC Form D filings
- Corey GoodmanDirectorNamed in SEC Form D filings
- Glen FirestoneExecutive OfficerNamed in SEC Form D filings
- Greg BellExecutive OfficerNamed in SEC Form D filings
Show all 15 people
- Gregory BellExecutive OfficerNamed in SEC Form D filings
- Jake BauerDirectorNamed in SEC Form D filings
- James TestaExecutive OfficerNamed in SEC Form D filings
- Mark TimneyExecutive Officer, DirectorNamed in SEC Form D filings
- Mehdi KhodadadExecutive OfficerNamed in SEC Form D filings
- Nancy Miller-RichDirectorNamed in SEC Form D filings
- Rahul KakkarDirectorNamed in SEC Form D filings
- Richard GasterDirectorNamed in SEC Form D filings
- Spencer GuthrieExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 12- PendingAntibody-peptide Fusion Proteins For Treating Amyloid DisordersUSPTOApplication 18907295
- GrantedAntibody-peptide Fusion Proteins For Treating Amyloid DisordersUSPTOUS 12,139,529
- PendingPeptide-fc Fusions For Treating Amyloid DisordersUSPTOApplication 18289032
Show all 12 patent records
- Antibody-peptide Fusion Proteins For Treating Amyloid DisordersMar 27, 2025 · Application 18907295Pending
- Antibody-peptide Fusion Proteins For Treating Amyloid DisordersNov 12, 2024 · US 12,139,529Granted
- Peptide-fc Fusions For Treating Amyloid DisordersJul 4, 2024 · Application 18289032Pending
- Peptide-fc Fusions For Treating Amyloid DisordersApplication PCTUS2022072112Pending
- Antibody-peptide Fusion Proteins For Treating Amyloid DisordersApplication 63190191Pending
- Peptide-fc Fusions For Treating Amyloid DisordersApplication 63186605Pending
- Peptide-fc Fusions For Treating Amyloid DisordersApplication 63184682Pending
- Sap Fc Fusion Proteins And Methods Of UseApplication 63153777Pending
- Modified Immunoglobulins For Targeting Amyloid DepositsApplication PCTUS2020060596Pending
- Sap Fc Fusion Proteins And Methods Of UseApplication 63108799Pending
- Fusion Proteins That Bind Amyloid And The Transferrin Receptor And Uses ThereofApplication PCTUS2023079673Pending
- Antibody-peptide Fusion Proteins For Treating Amyloid DisordersApplication PCTUS2022072413Pending
Related companies, and why
- IRONWOOD PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
- Lycia TherapeuticsSimilar federal contract value in Biotech · null in contracts
- BioNTech SESimilar federal contract value in Biotech · null in contracts
- NEONC TECHNOLOGIES HOLDINGS, INC.Similar federal contract value in Biotech · null in contracts
- Aeovian PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- ILiAD BiotechnologiesSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .